This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal

Experience in Normal Subjects and in Patients with Myocardial Abnormality

SAMUEL BELLET, M.D.; D. FINKELSTEIN, M.D.; H. GILMORE, M.D.

AMA Arch Intern Med. 1957;100(5):750-758.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Since 1918 quinidine has been used successfully in the treatment and prevention of various cardiac arrhythmias, particularly extrasystoles, paroxysmal tachycardia, atrial fibrillation, and flutter. Since the oral ingestion of quinidine derivatives reach a blood plasma peak relatively quickly and the concentration following a single dose falls rather rapidly,^1-5 it is necessary to administer not only multiple daily doses but frequently night doses to maintain an effective plasma level. In order to avoid multiple doses, attempts have been made at various times to administer a slower- and longer-acting preparation. Sampson et al. (1952),⁶ in an effort to find a more slowly absorbed and longer-acting preparation of quinidine, used a delayed-absorptive-coated tablet of quinidine sulfate. They gave 0.8 gm. as a single dose to five patients. The maximum quinidine level, which ranged from 2.3 to 3.3 mg. per liter (average, 2.72 mg. per liter) was reached in 5 to 12 . . . [Full Text PDF of this Article]

Author Affiliations
Philadelphia

From the Division of Cardiology of the Philadelphia General Hospital and the Graduate Hospital and Robinette Foundation of the University of Pennsylvania. Director, Division of Cardiology, Philadelphia General Hospital, and Director, Division of Cardiovascular Disease, Graduate Hospital, University of Pennsylvania (Dr. Bellet); Associate Physician, Graduate Hospital, University of Pennsylvania, and Assistant Cardiologist, Philadelphia General Hospital (Dr. Finkelstein); National Heart Institute Trainee (Dr. Gilmore).

Footnotes
Submitted for publication March 28, 1957.

This work was aided by grants from the U. S. Public Health Service (Grant H. 146C7), the Foundation for Cardiovascular Research, and the Wynn Pharmacal Corporation of Pennsylvania.